Author

Diann L. Blanset

Observed names: Blanset Diann L., Blanset, Diann, D Blanset, D. Blanset, Diann Blanset

Observed institutions: Southern Research Institute, National Institutes of Health, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Innsbruck Medical University, Medical University of Białystok, University of Cologne, Bristol-Myers Squibb (United States), National Cancer Institute, American Health Network, Boehringer Ingelheim (United States), Bloomsbury Publishing (United Kingdom), The Ohio State University, University of Cincinnati, University of Pennsylvania

OpenAlex ID: A5110192129

In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates

2014 · Changyu Wang, Kent B. Thudium, et al. · Cancer Immunology Research · 602

Phase I/II Study of an Anti-CD30 Monoclonal Antibody (MDX-060) in Hodgkin's Lymphoma and Anaplastic Large-Cell Lymphoma

2007 · Stephen M. Ansell, Steven M. Horwitz, et al. · Journal of Clinical Oncology · 251

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

2016 · S Hipp, Y-T Tai, et al. · Leukemia · 233

PDF

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

2016 · Mark J. Selby, John J. Engelhardt, et al. · PLoS ONE · 231

PDF

CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques

2006 · A. Hryniewicz, A. Boasso, et al. · Blood · 174

PDF

Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques

2003 · Tibor Keler, Ed Halk, et al. · The Journal of Immunology · 134

Use of Tissue Cross-reactivity Studies in the Development of Antibody-based Biopharmaceuticals

2010 · Michael W. Leach, Wendy G. Halpern, et al. · Toxicologic Pathology · 100

Prophylaxis and Therapy of Inhalational Anthrax by a Novel Monoclonal Antibody to Protective Antigen That Mimics Vaccine-Induced Immunity

2006 · Laura Vitale, Diann Blanset, et al. · Infection and Immunity · 91

A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies

2009 · Pina M. Cardarelli, Chetana Rao-Naik, et al. · Cancer Immunology Immunotherapy · 47

Erratum: A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

2017 · S Hipp, Y-T Tai, et al. · Leukemia · 45

Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology

2013 · Stanley A. Roberts, Paul A. Andrews, et al. · Regulatory Toxicology and Pharmacology · 45

Probabilistic Estimates of Lifetime Daily Doses from Consumption of Drinking Water Containing Trace Levels ofN,N-diethyl-meta-toluamide (DEET), Triclosan, or Acetaminophen and the Associated Risk to Human Health

2007 · Diann L. Blanset, Junfeng (Jim) Zhang, et al. · Human and Ecological Risk Assessment An International Journal · 41

Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial

2012 · Christopher Horvath, Laura Andrews, et al. · Nature reviews. Immunology · 37

Preclinical safety evaluations supporting pediatric drug development with biopharmaceuticals: strategy, challenges, current practices

2011 · LaRonda L. Morford, Christopher J. Bowman, et al. · Birth Defects Research Part B Developmental and Reproductive Toxicology · 37

Regulatory Consideration for the Nonclinical Safety Assessment of Gene Therapies

2022 · Jeffrey S. Moffit, Diann L. Blanset, et al. · Human Gene Therapy · 36

Correction: Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

2016 · Mark J. Selby, John J. Engelhardt, et al. · PLoS ONE · 32

PDF

Applying a weight of evidence approach to the evaluation of developmental toxicity of biopharmaceuticals

2018 · Meredith Rocca, LaRonda L. Morford, et al. · Regulatory Toxicology and Pharmacology · 27

Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices

2020 · Matthew S. Bogdanffy, Jacob Lesniak, et al. · International Journal of Toxicology · 21

Analysis of exposure margins in developmental toxicity studies for detection of human teratogens

2019 · Paul A. Andrews, Diann Blanset, et al. · Regulatory Toxicology and Pharmacology · 21

Phase I Study Evaluating the Safety and Pharmacokinetics of MDX-1303, a Fully Human Monoclonal Antibody against Bacillus anthracis Protective Antigen, in Healthy Volunteers

2011 · Valerie Riddle, Phillip Leese, et al. · Clinical and Vaccine Immunology · 18

BI 836909, a Novel Bispecific T Cell Engager for the Treatment of Multiple Myeloma Induces Highly Specific and Efficacious Lysis of Multiple Myeloma Cells in Vitro and Shows Anti-Tumor Activity in Vivo

2015 · Susanne Hipp, Petra Deegen, et al. · Blood · 17

Classic and evolving approaches to evaluating cross reactivity of mAb and mAb-like molecules – A survey of industry 2008–2019

2021 · Timothy K. MacLachlan, Shari Price, et al. · Regulatory Toxicology and Pharmacology · 13

Current use of animal models of disease for nonclinical safety testing

2020 · Diann Blanset, Julie Hutt, et al. · Current Opinion in Toxicology · 9

Erratum: Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial

2012 · Christopher Horvath, Laura Andrews, et al. · Nature reviews. Immunology · 9

PDF

THU0407 Preclinical Characterization of a Highly Selective and Potent Antagonistic Anti-CD40 mAb

2015 · K. Ralph, A. Nicoletti, et al. · Annals of the Rheumatic Diseases · 8

Works count: 55

Citation count: 2,310

H-index: 19

I10-index: 22